Chongqing Genrix Biopharmaceutical Co., Ltd. (SHA:688443)

SHA:688443 Revenue

Chongqing Genrix Biopharmaceutical had revenue of 85.86M CNY in the quarter ending June 30, 2026, with 240.21% growth. This brings the company's total for the last twelve months to 338.44M, up 348.41% year-over-year. In the year 2025, Chongqing Genrix Biopharmaceutical had annual revenue of 230.73M with 666.66% growth. That makes Chongqing Genrix Biopharmaceutical the 27,892nd largest company in the world by revenue and 4,802nd in China.

• Revenue (ttm): 338.44M
• Revenue Growth: +348.41%
• P/S Ratio: 24.79
• Revenue / Employee: 298.71K
• Employees: 1,133
• Market Cap: 8.39B

Revenue Chart

Chart

Chart

Revenue by Geography

Chart

• Overseas 132.51M 57.4%
• China 98.19M 42.6%

Fiscal year ended Dec 31, 2025 See the full SHA:688443 breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	230.73M	200.63M	666.66%
Dec 31, 2024	30.09M	28.88M	2,384.11%
Dec 31, 2023	1.21M	736.26K	154.92%
Dec 31, 2022	475.24K	-38.72M	-98.79%
Dec 31, 2021	39.19M	38.10M	3,502.99%

Data Source: S&P Global Market Intelligence Last updated: Aug 30, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Oct 21, 2026

Data Sources Report a data error